Bone Health

ClinicalJuly 26, 2026

Clinical Trial on Abaloparatide's Impact on Bone Quality in Osteoporotic Patients

A clinical trial is assessing the efficacy of abaloparatide in improving bone density and reducing postoperative complications in osteoporotic patients undergoing spinal surgery.

Companies

Assets

Recent signals(12)

FDA accepts supplemental application for Alendronate Sodium by Apotex

Study on Bone Loss in Anorexia Nervosa Patients to Assess Bone Density and Hormonal Factors

FDA Approval Process Update for Alendronate Sodium by Impax Labs

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

FDA Grants AP Status for Alendronate Sodium ANDA206387 by IPCA Labs

Clinical Trial on Abaloparatide's Impact on Bone Quality in Osteoporotic Patients

FDA Approves Supplement for Alendronate Sodium by Rising

Study to Develop Risk Prediction Model for Medication-Related Osteonecrosis of the Jaw

FDA Accepts Supplement Application for Zoledronic Acid by Mylan Labs

FDA Grants AP Status for Alendronate Sodium ANDA206387

FDA Submission Update for Prolia (Denosumab) by Amgen

Aurobindo Pharma's Risendronate Sodium ANDA Submission Receives AP Status

Upcoming catalysts

Indications

Get signals before the market moves